Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in Type 2 diabetes mellitus

被引:22
|
作者
Qiu-Yue, Wang [1 ]
Fen-Qin, Chen [1 ]
机构
[1] China Med Univ, Affiliated Hosp 1, Dept Endocrinol, Shenyang 110001, Peoples R China
关键词
Diabetes mellitus; Diabetic nephropathy; Monocyte chemoattractant protein-1; KAPPA-B ACTIVATION; MYCOPHENOLATE-MOFETIL; NEPHROPATHY; SPIRONOLACTONE; ASSOCIATION; INJURY; MCP-1;
D O I
10.1016/j.diabres.2008.09.048
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Monocyte chemoattractant protein-1(MCP-1) is a cytokine that exhibits most potent chemotactic activity toward monocytes. It is suggested to be implicated in the development and progression of diabetic nephropathy by playing a role in infiltration of monocyte/macrophage. Recent studies have demonstrated that urinary monocyte chemoattractant protein-1 (uMCP-1) is different at different stages of diabetic nephropathy. Based on these findings, the aim of this study is to examine the level of uMCP-1 and its clinical significance at different stages of diabetic nephropathy and at the same time to describe the relationship between uMCP-1 and the various parameters. Methods: Fifty-nine cases with type 2 diabetes mellitus (T2DM) were divided into three groups according to urine albumin excretion (UAE): normal albuminuria group, microalbuminuria group and macroalbuminuria group. The levels of uMCP-1, protein excretion, blood urea nitrogen (BUN), serum creatinine (s-Cr), glycohemoglobin A1c (HbA1c), blood pressure and blood fat were measured in 59 patients with T2DM and 27 healthy adults as controls. Results Compared with normal control, levels of uMCP-1 in T2DM were significantly high, which were already elevated in normal albuminuria group. Compared with normal albuminuria group, levels of uMCP-1 in microalbuminuria group and macroalbuminuria group were significantly high. Levels of uMCP-1 in macroalbuminuria group were higher than those in microalbuminuria group. The level of uMCP-1 was positively correlated with UAE, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) in T2DM patients, while it had no significant correlation with HbA1c, triglyceride (TG) and high density lipoprotein cholesterol (HDL-C). Conclusions: MCP-1 is suggested to be implicated in the development and progression of diabetic nephropathy. it is very important to measure the level of uMCP-1 in the diagnosis and intervention of early diabetic nephropathy. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 50 条
  • [21] MONOCYTE CHEMOATTRACTANT PROTEIN-1 SERUM LEVELS IN DEPENDING ON HISTORY OF PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH CORONARY ARTERY DISEASE WITH TYPE 2 DIABETES MELLITUS
    Mavrycheva, N.
    Serik, S.
    ATHEROSCLEROSIS, 2022, 355 : E103 - E103
  • [22] Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein-1 that are not influenced by the-2518 A→G promoter polymorphism
    Zietz, B
    Büchler, C
    Herfarth, H
    Müller-Ladner, U
    Spiegel, D
    Schölmerich, J
    Schäffler, A
    DIABETES OBESITY & METABOLISM, 2005, 7 (05): : 570 - 578
  • [23] Association of polymorphisms in monocyte chemoattractant protein-1 promoter with diabetic kidney failure in Korean patients with type 2 diabetes mellitus
    Moon, Ju-Young
    Jeong, Laeik
    Lee, Sangho
    Jeong, Kyunghwan
    Lee, Taewon
    Ihm, Chun-Gyoo
    Suh, Jungho
    Kim, Junghee
    Jung, Yoo-Yeon
    Chung, Joo-Ho
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 (05) : 810 - 814
  • [24] Plasma monocyte chemoattractant protein-1 as risk marker in type 2 diabetes mellitus and coronary artery disease in North Indians
    Harsimran, Kaur
    Singh, Arora Ajinder Pal
    Guruvinder, Singh
    Sharda, Sidhu
    Vasudha, Sambyal
    DIABETES & VASCULAR DISEASE RESEARCH, 2009, 6 (04): : 288 - 290
  • [25] Monocyte chemoattractant protein-1 in obesity and type 2 diabetes.: Insulin sensitivity study
    Chacon, Matilde R.
    Fernandez-Real, Jose Manuel
    Richart, Cristobal
    Megia, Ana
    Gomez, Jose Manuel
    Miranda, Merce
    Caubet, Enric
    Pastor, Rosa
    Masdevall, Carles
    Vilarrasa, Nuria
    Ricard, Wifredo
    Vendrell, Joan
    OBESITY, 2007, 15 (03) : 664 - 672
  • [26] Association of Monocyte Chemoattractant Protein-1 (MCP-1) 2518 A/G Polymorphism with Obesity in Korean Type 2 Diabetes Mellitus
    Park, Sangshin
    Lee, Dong-Hwa
    Lee, Shinyoung
    Jeon, Hyun Jeong
    DIABETES METABOLIC SYNDROME AND OBESITY, 2024, 17 : 3917 - 3924
  • [27] 9 Monocyte chemoattractant protein-1 as a biomarker of vascular dysfunction in patients with type 2 diabetes
    MacDonald, William
    Casanova, Francesco
    Gooding, Kim
    Aizawa, Kuni
    Shore, Angela
    Khan, Faisel
    HEART, 2023, 109 (SUPPL_2) : A4 - A4
  • [28] Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes
    Chiarelli, F
    Cipollone, F
    Mohn, A
    Marini, M
    Iezzi, A
    Fazia, M
    Tumini, S
    De Cesare, D
    Pomilio, M
    Pierdomenico, SD
    Di Gioacchino, M
    Cuccurullo, F
    Mezzetti, A
    DIABETES CARE, 2002, 25 (10) : 1829 - 1834
  • [29] Effects of spironolactone on oxidative stress and urinary monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by diabetic nephropathy
    Takebayashi, Kohzo
    Matsumoto, Sachiko
    Suetsugu, Mariko
    Wakabayashi, Sadao
    Aso, Yoshimasa
    Inukai, Toshihiko
    DIABETES, 2006, 55 : A135 - A135
  • [30] Urinary Monocyte Chemoattractant Protein-1 in Patients With Alport Syndrome
    Kashtan, Clifford
    Schachter, Asher
    Klickstein, Lloyd
    Liu, Xin
    Jennings, Lori
    Finkel, Nancy
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (07): : 1112 - 1114